Received Aug 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
COVID-19; Flu; Sinus infection; Bronchitis; Ear infection; This non-serious case was reported by a consumer via call center representative and described the occurrence of covid-19 in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. Additional patient notes included the patient having other conditions. On 17-FEB-2025, the patient received the 1st dose of Shingrix. On an unknown date, less than 6 months after receiving Shingrix, the patient experienced covid-19 (Verbatim: COVID-19), influenza (Verbatim: Flu), sinus infection (Verbatim: Sinus infection), bronchitis (Verbatim: Bronchitis) and ear infection (Verbatim: Ear infection). The outcome of the covid-19, influenza, sinus infection, bronchitis and ear infection were unknown. It was unknown if the reporter considered the covid-19, influenza, sinus infection, bronchitis and ear infection to be related to Shingrix. It was unknown if the company considered the covid-19, influenza, sinus infection, bronchitis and ear infection to be related to Shingrix. Additional Information: GSK receipt date: 18-JUL-2025 The patient received first shot of Shingrix and had experienced covid, flu, sinus infection, and ear infections on the past 6 months. The reason for no batch or lot number of Shingrix was discarded.
Comments: the patient having other conditions